Watch this enlightening conversation focused on the transforming power of antibody-drug conjugates (ADCs) like T-DXd (trastuzumab deruxtecan) in HER2-positive breast cancer therapy with Dr. Anne O’Dea and Dr. VK Gadi. The doctors provide hope for T-DXd’s potential usage as a first-line treatment, which could change present guidelines away from conventional chemotherapy treatments like the Cleopatra regimen, notable for their high toxicity. Effective, focused therapy with less side effects provided by T-DXd could improve patients’ quality of life and maybe increase general survival.They also discuss the value of HER2 testing, pointing out that patients labeled as HER2-low or ultra-low could still benefit from T-DXd , therefore stressing the need of more exact diagnostic criteria. Trials like DB12 and DESTINY-Breast06 under progress allow Dr. O’Dea and Dr. Gadi optimism for improved understanding of ideal therapy sequencing, particularly for managing brain metastases—a major difficulty in HER2-positive cases.Emphasizing personalizing, strategic sequencing, and future research to generate better outcomes and, finally, the possibility for more curative medicines, their discussion shows an emerging approach to HER2 treatment.🎧 Don’t forget to like, share, and subscribe for more CHM Conversations#BreastCancer #OncologyPodcast #TDXd #HER2Low #CHMConversations #PrecisionMedicine #CancerResearch–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Join Dr. VK Gadi and Dr. Jason Mouabbi at a recent conference for their discussion around the changing function of antibody-drug conjugates (ADCs) such as T-DXd (trastuzumab deruxtecan) in treating HER2-positive breast cancer, especially in patients with central nervous system (CNS) metastases. The talk hinges on the historical use of tiny compounds like tucatinib to ensure they’re able to pass the blood-brain barrier. New research, however, challenges the conventional wisdom on treatment restrictions by showing that ADCs might also be useful in this environment.

Dr. Mouabbi offered a real-world illustration of T-DXd’s transforming power by sharing a clinical case whereby it produced amazing regression of both visceral and central nervous system disorders. Data from studies like as DESTINY-Breast04 and the forthcoming DB12 study, which concentrates on patients with untreated or stable brain metastases, could provide vital direction on T-DXd’s efficacy in CNS care. In line with the encouraging findings observed in clinical practice, this trial seeks to confirm T-DXd’s influence on brain metastases.

The discussion also touches on the need for closely monitoring patients, especially for possible side effects including interstitial lung disease (ILD), with doctors using routine CT imaging and pulmonary function testing. Dr. Mouabbi underlined that novel treatments such as T-DXd represent a turning point in the field and give patients with metastatic breast cancer hitherto unheard-of hope.

You can watch the full conversation between Dr. Gadi and Dr. Mouabbi below to hear more of their experience and analysis of how ADCs are changing HER2-positive breast cancer treatment, therefore offering patients with advanced illness more focused and efficient choices.

🎧 Don’t forget to like, share, and subscribe for more CHM Conversations

#BreastCancer #OncologyPodcast #TDXd #HER2Low #CHMConversations #PrecisionMedicine #CancerResearch

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

What happens when MD Anderson’s translational firebrand Jason Mouabbi sticks a microphone in front of long-time HER2 guru Mothaffar Rimawi just days after the first read-out of DESTINY-Breast09? In sixty candid minutes they chart how trastuzumab deruxtecan (T-DXd) ± pertuzumab vaulted past CLEOPATRA; posting a headline 41-month PFS that forces oncologists to rethink induction/maintenance dogma, sequencing, and even the forbidden word “cure.” in what was previously considered uncurable. Along the way they debate ILD fears, whether any patient should ever leave the clinic without concurrent endocrine therapy, and christen T-DXd as “the great equalizer” for tumors burdened by ESR1, PIK3CA or BRCA mutations. By the end, Dr. Rimawi’s motto “put your best player in at kickoff” feels less like a bravado and more like the tomorrow’s standard of care.

Why you’ll want to listen

• Design matters: how DB-09’s two experimental arms (T-DXd alone vs T-DXd + pertuzumab) were built to settle the dual-blockade question once and for all.

• A 41-month shockwave: the largest PFS ever seen in metastatic HER2-positive breast cancer—and why it may still climb.

• Induction vs “until further notice”: can oncologists still offer a chemo-free maintenance phase, or does the ADC stay on forever?

• ILD in real life: 12 % remains, but community doctors already trade scheduled breaks for lower risk without sacrificing depth of response.

• Sequencing after an early ADC: if T-DXd moves up front, what’s left for tucatinib, T-DM1 or neratinib and more importnatly does it matter?

• Cure? Dare we say it: Rimawi argues we are “closest in any solid tumor” to normal life expectancy; Dr. Mouabbi pushes him to define what bold looks like.

• Endocrine cross-talk—still ignored: fewer than 10 % of DB-09 patients got concomitant endocrine therapy despite 60 % ER-positivity, a missed chance the speakers vow to fix.

• PI3K mutation? Payload doesn’t care: why the ADC’s topoisomerase warhead levels the playing field across resistance genotypes.

🎧 Like, share, and subscribe for more CHM Conversations that turn headline data into bedside decisions.

#BreastCancer #HER2Positive #TDXd #DESTINYBreast09 #OncologyPodcast #PrecisionMedicine #CHMConversations

–

Thanks for listening!

Our podcasts are also available on:

• Youtube - youtube.com/@CommunityHealthMedia

• Amazon Music - amazn.so/chm-podcast

• Apple Podcast - podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - castbox.fm/vh/6735434

• Goodpods - goodpods.com/profile/chm-111066

• iHeartRadio - iheart.com/podcast/291542082

• Pocket Casts - pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

What happens when an MD Anderson breast oncology investigator Dr. Mouabbi sits down with a high-volume community oncologist Dr. Cairo, who now treats the same patients the trials were written for? Over one fast-moving hour, they chart the collapse of the old HER2 binary, weigh DESTINYBreast 04 against 06, and admit that practicing oncologists still hesitate to jump straight from endocrine therapy to trastuzumab deruxtecan (TDXd) when trusty capecitabine is sitting on the shelf. They swap war stories about persuading pathology to report “ultralow” staining, debate whether any historical 1+ slide is enough to warrant an ADC, and reveal why “whichever ADC you give first is going to be your best ADC.” The conversation converges into ILD pragmatics, that is, community clinicians, it seems, aren’t the least bit afraid before landing on a new term the duo coined on air: “endocrine dynamics,” that is, the art of cycling back to hormones once the aggressive clone is beaten down by an ADC.

Highlights you’ll hear: the trial-by-trial evolution from DB04 to DB06 and why ultralow tumors now matter; capecitabine versus the allure of earlier ADCs; ultralow testing bottlenecks and the coming ASCOCAP guideline shakeup; sequencing philosophies (sandwich vs back-to-back) and their payload implications; real-world ILD management that’s less daunting than advertised; and, at the close, a playful wager on whether we’ll soon treat every HR-positive case as “ADC-eligible” until true zero is finally defined.

🎧 Listen, share, and subscribe for more CHM Conversations that fuse bigtrial evidence with the front lines

#BreastCancer #HER2Low #Ultralow #TDXd #ADCSequencing #OncologyPodcast #CHMConversations

–

Thanks for listening!

Our podcasts are also available on:

• Youtube - youtube.com/@CommunityHealthMedia

• Amazon Music - amazn.so/chm-podcast

• Apple Podcast - podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - castbox.fm/vh/6735434

• Goodpods - goodpods.com/profile/chm-111066

• iHeartRadio - iheart.com/podcast/291542082

• Pocket Casts - pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

When the binary “HER2-positive vs HER2-negative” model collapsed under the weight of DESTINY-Breast04 and 06, the real work began: deciding who should receive trastuzumab deruxtecan (T-DXd), when to leapfrog chemotherapy, and how to keep quality of life front-and-center. In this interactive Live from Seattle stream, translational researcher & clinician Dr. V.K. Gadi and high-volume breast oncologist Dr. Fengting Yan wrestle with that nuance in front of a virtual audience. Drawing on SABCS sub-analyses, ASCO 2025 biomarker updates, and their own experience and anecdotes, they outline a decisional playbook that blends disease-burden triage, endocrine-resistance patterns, and the evolving spectrum of HER2 testing from IHC 3+ to “ultralow” 0.1 %.

Whether you manage trials, beds, or databases, this hour distills the fast-moving ADC landscape into pragmatic rules of thumb and flags the knowledge gaps that still separate evidence from art.

Topics include:

• HER2 re-imagined: from a rigid binary to a four-tier lexicon (positive, low, ultralow, zero) and why pathologists now add “ultralow” to reports.

• DESTINY-Breast04 vs 06 head-to-head: why chemo-naïve, HR-positive patients doubled objective response (57 % vs 32 %) and what that means for first post-endocrine standard of care.

• Disease-burden triage: T-DXd first for “angry livers” and visceral-crisis lung mets; oral agents still reasonable for indolent bone-only progressors.

• Endocrine exhaustion vs sub-optimal use: ESR1 mutation, shrinking ER staining, and ≤6-month PFS as triggers to skip another endocrine line and go straight to an ADC.

• Sequencing before traditional chemo: weighing physician-choice capecitabine against IV T-DXd after DB-06 — and the lingering fear of closing off later options.

• Safety & survivorship: keeping ILD in check while troubleshooting weight-gain, nausea, and fatigue before cutting the dose.

• ADC-after-ADC Sandwich? emerging data on payload switching and why some clinicians are abandoning the “sandwich” doctrine to front-load the most active agents.

• Real-world evidence 2.0: how AI-curated registries are validating clinical-trial deltas across messy geographies and comorbidity spectra.

• Future watch-list: DB-09, NeoCARHP and biomarker-guided de-escalation trials, e.g. ATEMPT 2.0 that might finally limit indefinite therapy.

🎧 Like, share, and subscribe for more CHM Conversations that translate headline data into bedside decisions

#BreastCancer #HER2Low #Ultralow #TDXd #OncologyPodcast #CHMConversations

–

Thanks for listening!

Our podcasts are also available on:

• Spotify - spotf.fi/chm-podcast

• Amazon Music - amazn.so/chm-podcast

• Apple Podcast - podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - castbox.fm/vh/6735434

• Goodpods - goodpods.com/profile/chm-111066

• iHeartRadio - iheart.com/podcast/291542082

• Pocket Casts - pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

In this insightful CHM Conversations episode, Drs. Callahan & Bardia delve deep into the evolving definitions of HER2 positivity (and negativity, or lack of HER2) in breast cancer and the transformative impact of trastuzumab deruxtecan (T-DXd) especially in metastatic cases. From groundbreaking historical discoveries to recent clinical trial advancements, they critically examine how HER2 classifications, have moved on from binary to a continuum from low to even ultra-low expression and are reshaping therapeutic paradigms and patient care decisions. Key insights into managing brain metastases, T-DXd associated pneumonitis, optimizing treatment sequencing, and effectively communicating complex medical data to patients highlight the conversation. This episode is essential listening for oncologists, researchers, and advocates interested in the latest shifts in breast cancer therapy.

Topics Covered:

• Historical evolution of HER2 classifications

• Clinical impact of HER2 low and ultra-low categorizations

• DESTINY-Breast trials and groundbreaking T-DXd data

• Management strategies for brain metastases, T-DXd associated pneumonitis

• Patient-centered communication and shared decision-making

🎧 Don’t forget to like, share, and subscribe for more CHM Conversations

#HER2 #TDXd #MetastaticBreastCancer #BreastCancerResearch #OncologyEducation #CHMConversations #DESTINYBreast04 #FirstLineTherapy #CancerCare

–

Thanks for listening!

Our podcasts are also available on:

• Youtube - youtube.com/@CommunityHealthMedia

• Amazon Music - amazn.so/chm-podcast

• Apple Podcast - podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - castbox.fm/vh/6735434

• Goodpods - goodpods.com/profile/chm-111066

• iHeartRadio - iheart.com/podcast/291542082

• Pocket Casts - pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

In this episode of CHM Conversations, two of breast oncology’s brightest specialists — Dr. Jason Mouabbi and Dr. Paolo Tarantino — explore how trastuzumab deruxtecan (T-DXd) has fundamentally restructured therapeutic strategies across HER2-positive and HER2-low disease, while “curing” what was once thought to be really aggressive disease. From the transformative DESTINY-Breast trials to the evolving art of real-world clinical decision-making, they dissect not only the science and trial data but the shifting frameworks now guiding oncologists at the bedside.

They critically examine how T-DXd, once a remarkable agent for refractory HER2+ tumors, is now reshaping standards in HER2-low and ultra-low settings, overcoming historical binaries of HER2 classification. Their conversation traverses management of brain metastases, individualized sequencing to mitigate ILD risks, and emerging strategies to move away from indefinite therapy models. Importantly, they emphasize the growing need for precision-driven, patient-centered oncology at a time when therapeutic options are expanding faster than rigid guidelines can adapt.

Whether you're a healthcare provider, researcher, or patient advocate, this is a must-listen episode that offers deep insight into one of the most promising advances in breast cancer therapy.

🔬 Topics include:

• The T-DXd era: from preclinical promise to clinical breakthrough

• Reframing HER2 biology: Low and ultra-low as therapeutic targets, not distinct entities

• Management of brain metastases

• Strategic dominance in metastatic disease: DESTINY-Breast03, 04, 06, and 12 insights

• Sequencing treatment strategies and minimizing ILD risk

• Minimizing ILD risk: The Five S's — Screen, Scan, Synergy, Suspend, Steroids

• The future of early-stage disease: Neoadjuvant and adjuvant trials challenging classical chemotherapy models

🎧 Don’t forget to like, share, and subscribe for more CHM Conversations

#BreastCancer #OncologyPodcast #TDXd #HER2Low #CHMConversations #PrecisionMedicine #CancerResearch

–

Thanks for listening!

Our podcasts are also available on:

• Youtube - youtube.com/@CommunityHealthMedia

• Amazon Music - amazn.so/chm-podcast

• Apple Podcast - podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - castbox.fm/vh/6735434

• Goodpods - goodpods.com/profile/chm-111066

• iHeartRadio - iheart.com/podcast/291542082

• Pocket Casts - pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media